Lakefront Biotherapeutics NV (LKFT)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Acquisition of Own Shares

Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase...

Lakefront Receives Transparency Notification from Madison Avenue Partners

Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Acquisition of Own Shares

Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information Within the framework of the repurchase...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Acquisition of Own Shares

Mechelen, Belgium; June 16, 2026, 22.01 CET; regulated information Within the framework of the repurchase...

Lakefront Announces Initiation of €50 Million Stock Repurchase Program

Mechelen, Belgium; June 9, 2026, 22:01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext...

Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer

Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today...

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T...

Lakefront Receives Transparency Notification from Bank of America

Mechelen, Belgium; May 26, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext...